Sec Form 3 Filing - Muckenhirn Keith E @ ANTARES PHARMA, INC. - 2016-09-04

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Muckenhirn Keith E 2. Issuer Name and Ticker or Trading Symbol ANTARES PHARMA, INC. [ ATRS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) VP/Controller & Interim CFO (Last) (First) (Middle) C/O ANTARES PHARMA, INC., 100 PRINCETON SOUTH, SUITE 300 3. Date of Earliest Transaction (MM/DD/YY) 09/04/2016 (Street) EWING, NJ08628 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 50,000 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 1.23 01/16/2010( 1 ) 01/15/2017 Common Stock $0.01 par value per share 30,000 D Stock Option (right to buy) $ 1.65 05/10/2010( 1 ) 05/09/2017 Common Stock $0.01 par value per share 15,000 D Stock Option (right to buy) $ 0.85 05/14/2011( 1 ) 05/13/2018 Common Stock $0.01 par value per share 45,000 D Stock Option (right to buy) $ 0.47 11/12/2011( 1 ) 11/11/2018 Common Stock $0.01 par value per share 20,000 D Stock Option (right to buy) $ 1.1 11/11/2012( 1 ) 11/11/2019 Common Stock $0.01 par value per share 45,000 D Stock Option (right to buy) $ 1.52 11/11/2013( 1 ) 11/10/2020 Common Stock $0.01 par value per share 35,000 D Stock Option (right to buy) $ 2.94 05/17/2015( 1 ) 05/16/2022 Common Stock $0.01 par value per share 20,000 D Stock Option (right to buy) $ 3.96 05/22/2016( 1 ) 05/22/2023 Common Stock $0.01 par value per share 30,000 D Stock Option (right to buy) $ 2.29 ( 2 ) 11/19/2024 Common Stock $0.01 par value per share 35,000 D Stock Option (right to buy) $ 3.09 ( 3 ) 05/29/2024 Common Stock $0.01 par value per share 35,000 D Stock Option (right to buy) $ 2.18 ( 4 ) 05/28/2025 Common Stock $0.01 par value per share 35,000 D Stock Option (right to buy) $ 1.12 ( 5 ) 06/02/2026 Common Stock $0.01 par value per share 40,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Muckenhirn Keith E C/O ANTARES PHARMA, INC. 100 PRINCETON SOUTH, SUITE 300 EWING, NJ08628 VP/Controller & Interim CFO Signatures Keith Muckenhirn 09/12/2016 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents grant of options to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The options vested in equal quarterly installments over three years from the initial grant date. The exercisable date listed above represents the date the options became fully vested and exercisable. ( 2 )Represents grant of options to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The options were granted on November 20, 2014 and are vesting in equal quarterly installments over three years from the initial grant date. ( 3 )Represents grant of options to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The options were granted on May 29, 2014 and are vesting in equal quarterly installments over three years from the initial grant date. ( 4 )Represents grant of options to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The options were granted on May 28, 2015 and are vesting in equal quarterly installments over three years from the initial grant date. ( 5 )Represents grant of options to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The options were granted on June 2, 2016 and are vesting in equal quarterly installments over three years from the initial grant date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.